Last reviewed · How we verify
Adaptive and Individualized AAC
NA trial testing Experimental AAC in Communication Disorders in 30 participants. Completed in 31 August 2021.
| Lead sponsor | Altec Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 6 January 2020 |
| Primary completion | 31 August 2021 |
| Estimated completion | 31 August 2021 |
| Sites | 2 locations across United States |
Altec Inc.
12 and older, any sex, with Communication Disorders. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Time needed to navigate a cursor to and select a target on a computer screen by control of head movement and facial muscle contractions for each AAC device, wherein lower movement times equate to better performance.
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 2.5 | ± 1.9 |
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 2.9 | ± 2.0 |
Path smoothness relative to the optimal, straight path between targets on a computer screen by control of head movement and facial muscle contractions for each AAC device. Variability is estimated as a distance of pixels as estimated from a computer screen operating with a resolution of 1920 pixels x 1080 pixels, wherein smaller variability scores equate to better performance.
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 49.7 | ± 9.4 |
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 74.0 | ± 9.5 |
Percentage of accurate selections of targets on a computer screen by control of head movement and facial muscle contractions for each AAC device, wherein higher accuracy scores equate to better performance.
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 96.3 | ± 6.3 |
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 94.5 | ± 9.8 |
Human motor performance relative to the speed and accuracy of cursor-to-target movements on a computer screen by control of head movement and facial muscle contractions for each AAC device, wherein higher information transfer rates equate to better performance.
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 45.8 | ± 20.0 |
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 36.6 | ± 16.2 |
Self-report of perceived AAC device usability as captured via a Likert scale anchored from 1 ("very difficult") to 7 ("very easy"), wherein higher usability scores equate to better performance.
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 4.7 | ± 1.7 |
| Group | Value | 95% CI |
|---|---|---|
| Experimental and Generic Communication Interfaces for AAC | 4.3 | ± 2.9 |
This project will test the feasibility of developing a smart augmentative or alternative communication (AAC) system that is effective in delivering communication capabilities that automatically adapt to the users' physical abilities.
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Trials testing the same drug.
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04247828.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing